U.S. markets open in 2 hours 44 minutes
  • S&P Futures

    3,810.25
    -17.00 (-0.44%)
     
  • Dow Futures

    30,938.00
    -123.00 (-0.40%)
     
  • Nasdaq Futures

    11,545.75
    -65.50 (-0.56%)
     
  • Russell 2000 Futures

    1,717.60
    -10.90 (-0.63%)
     
  • Crude Oil

    108.41
    -0.02 (-0.02%)
     
  • Gold

    1,803.00
    +1.50 (+0.08%)
     
  • Silver

    19.84
    +0.25 (+1.27%)
     
  • EUR/USD

    1.0304
    -0.0120 (-1.15%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • Vix

    28.06
    -0.65 (-2.26%)
     
  • GBP/USD

    1.2039
    -0.0065 (-0.54%)
     
  • USD/JPY

    135.8700
    +0.2100 (+0.15%)
     
  • BTC-USD

    19,741.51
    +263.35 (+1.35%)
     
  • CMC Crypto 200

    429.42
    +9.28 (+2.21%)
     
  • FTSE 100

    7,167.07
    -65.58 (-0.91%)
     
  • Nikkei 225

    26,423.47
    +269.66 (+1.03%)
     

Guardion Health Sciences Announces New Viactiv® Omega Boost Gel Bites Now Available for Purchase Via Viactiv® Shopify Store

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc.

Consumers May Now Purchase Viactiv® Omega Boost Directly from Viactiv.com

Viactiv® Omega Boost Gel Bites Provide 10x More Omega-3s Than the Leading Gummies, Without the Fishy Taste and Sugar Associated with Other Omega-3 Products

HOUSTON, April 11, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), a clinical nutrition company that develops clinically supported nutrition, medical foods, and supplements, today announces the availability of Viactiv® Omega Boost gel bites, the Company’s first expansion of the Viactiv® brand, via its branded Shopify store. The 1,200 mg Omega-3 gel bites are designed to provide total body support, including cardiovascular, brain, joint, and eye health, and can now be purchased at https://viactiv.com.

Previously, the Company had only been taking pre-orders for Viactiv® Omega BOOST gel bites.

“Now that our pre-orders have been fulfilled, we are ready and excited to accept direct orders for Viactiv® Omega Boost via our previously announced Shopify website,” commented Bret Scholtes, Guardion’s Chief Executive Officer. “This product launch is an important step in creating replicable processes that enable us to execute new product development, establish manufacturing, and accomplish marketing and distribution in a focused and efficient way. We continue to be excited to offer these important, supportive nutrients from our Viactiv® brand, the brand our customers have trusted for years and look forward to continuing to meet the nutritional supplement needs of our customers.”

“The Viactiv® Omega Boost product is a new dosage form that we believe addresses an existing gap in the Omega-3 market by providing clinically proven levels of Omega-3 in an easy to take, great tasting product,” added Craig Sheehan, Guardion’s Chief Commercial Officer.

The new dosage form provides the potency of large, hard-to-swallow soft gels, in a great tasting easy to chew format that contains ten times more Omega-3s than the leading fish oil gummy. The gel bite dosage form has been shown to have better absorption and fewer digestive issues than regular soft gel formulas, as well as no unpleasant fishy aftertaste and no sugar, all which can all be associated with other Omega-3 products.

About Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical nutrition company. Guardion’s portfolio of science-based, clinically supported nutrition, medical foods, and supplement products support healthcare professionals, their patients, and consumers in achieving health goals. The Company’s combination of expertise and scientifically supported products is the foundation of Guardion’s growing position within the clinical nutrition marketplace. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the U. S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

Forward-Looking Statement Disclaimer

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but are not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the integration of a new management team, the integration of one or more acquisitions and targets, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s listing requirements. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
CORE IR
Scott Arnold
516-222-2560
scotta@coreir.com

Media Relations Contact:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com